DUBLIN–(BUSINESS WIRE)–The “Global Phenylketonuria Treatment Market (2021-2026) by Type, Route, End-user, Geography, Competitive Analysis and the Impact of COVID-19 with Ansoff Analysis” report has been added to ResearchAndMarkets.com’s offering.
The Global Phenylketonuria Treatment Market is estimated to be USD 540.6 Mn in 2021 and is expected to reach USD 723.4 Mn by 2026, growing at a CAGR of 6%.
Key factors like the development of pipeline drugs against PKU along with market collaborations amongst the players have supported the growth of this market. Growing incidences of PKU patients worldwide is a major factor driving the growth of the global market. Several other factors, such as increasing investments in intensive research in the genomics field and increasing awareness regarding the timely treatment of PKU are responsible for spurring the growth of the phenylketonuria treatment market.
However, a high cost associated with the treatment of PKU, along with low awareness amongst the patients about the disease, has impeded the market growth.
Segments Covered
By Type, the Drugs segment is anticipated to grow at a faster pace in the forecasted period. It is because phenylketonuria is a rare genetic disorder with very few available treatment options so far. Healthcare professionals have widely promoted prescription drugs along with some dietary modifications. Out of which, Kuvan, a medical drug approved by the US FDA has been used for the treatment in tablet and powder form. Similarly, Biopten, manufactured by Daiichi Sankyo Co. Limited, has been approved by Japan, indicating the demand for this segment.
By Route Analysis, the Oral Route is anticipated to grow at a faster pace during the forecasted period. It is mainly due to the patients’ convenience for consumption and is also considered as an easy way of administration over intravenous injections/infusions.
By End User, the Hospital Pharmacies segment holds a major share of the market as they ensure the safe and effective use of medicines by carrying out medication reconciliation on admissions and changes in care level.
By Geography, North America is expected to lead the market. The factors attributing to the growth of this market are the favorable regulations and the Government initiatives towards the treatment of PKU, a rise in the number of new-born cases suffering from phenylketonuria, and a strong healthcare infrastructure system in the region. Additionally, there have been continuous R&D activities for the development and commercialization of new drugs for PKU, which has further promoted the growth of this market.
Why buy this report?
- The report offers a comprehensive evaluation of the Global Phenylketonuria Treatment Market.
- The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
- The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
- The report includes in-depth market analysis using Porter’s 5 force model and the Ansoff Matrix. The impact of COVID-19 on the market is also featured in the report.
- The report also contains the competitive analysis using Competitive Quadrant, the analyst’s proprietary competitive positioning tool.
Report Highlights:
- A complete analysis of the market including parent industry
- Important market dynamics and trends
- Market segmentation
- Historical, current, and projected size of the market based on value and volume
- Market shares and strategies of key players
- Recommendations to companies for strengthening their foothold in the market
Market Dynamics
Drivers
- Increasing Prevalence of Phenylketonuria
- Presence of Pipeline Drugs
- Rising Collaborations among Key Market Players
Restraints
- High Cost of Treatment
- Stringent Government Regulations
Opportunities
- Increasing Development and Commercialization of New Drugs
- Advancements in the Health Care Industry
Challenges
- Lack of Awareness among the Patients and Physicians
Trends
- Growing research in the field of genomics and bioinformatics
Companies Mentioned
- Homulogy Medicines, Inc.
- Rubius Therapeutics. Inc.
- Retrophin, Inc.
- Synlogic, Inc.
- BioMarin Pharmaceutical Inc.
- Daiichi Sankyo Company, Limited
- Codexis, Inc.
- SOM Innovation Biotech SL
- American Gene Technologies International Inc.,
- Erytech Pharma SA
- Dimension Therapeutics, Inc.
- Synthetic Biologics, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/5pea6l
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900